Drug Profile
SNA 02
Alternative Names: SNA-02Latest Information Update: 03 Mar 2021
Price :
$50
*
At a glance
- Originator Academia Sinica
- Developer Oneness Biotech
- Class Antineoplastics; Immunotherapies; Nucleotide aptamers
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Mar 2021 Preclinical development is ongoing for Cancer in Taiwan (Parenteral) (Microbio group pipeline, March 2021)
- 03 Mar 2021 Oneness Biotech plans a clinical trial for Cancer (Microbio group, March 2021)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Taiwan (Parenteral)